drugset
drugset / Trial / NCT04413279

Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease

NCT04413279 ↗

Phase 4 Completed 20 enrolled Eye Surgeons of Indiana Ocular Therapeutix, Inc. · collab
Non-randomizedCrossoverSingle-blindTreatment

Summary

To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in evaporative dry eye disease (DED) patients with meibomian gland disfunction (MGD) and underlying inflammation undergoing LipiFlow Thermal Pulsation.

Timeline

Start
2020-08-01
Primary completion
2021-07-01
Completion
2021-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 0.4 mg Other

Indications

dry eye syndrome